SEC Form 3 · accession 0001387131-15-000711
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Avner Ingerman
Officer — Chief Clinical Officer
Period of report
Feb 24, 2015
Accepted (ET)
Mar 2, 2015 · 10:58 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | holding | — | — | — | 1,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF1,F2 | $7.06 | holding | — | — | — | Mar 1, 2015 | Mar 1, 2020 | Common Stock | 200,000 | — | D |
| Restricted Stock UnitF4,F3 | — | holding | — | — | — | Mar 1, 2015 | — | Common Stock | 60,000 | — | D |
Explanation of responses
- F1150,000 options currently unexercisable; 50,000 options will become exercisable on each of December 31, 2015, December 31, 2016, and December 31, 2017.
- F275,000 options are subject to stockholder approval of the increase in share available under the Company's 2014 Stock Incentive Plan.
- F3These restricted stock units were granted on March 1, 2015; 30,000 units vest on January 1, 2016 and 15,000 units vest on each of January 1, 2017 and January 1, 2018.
- F4Each restricted stock unit represents the right to receive, at vesting, one share of common stock.